BRPI0409450A - composições que contêm peperacilina e tazobactamo, úteis para injeção - Google Patents

composições que contêm peperacilina e tazobactamo, úteis para injeção

Info

Publication number
BRPI0409450A
BRPI0409450A BRPI0409450-6A BRPI0409450A BRPI0409450A BR PI0409450 A BRPI0409450 A BR PI0409450A BR PI0409450 A BRPI0409450 A BR PI0409450A BR PI0409450 A BRPI0409450 A BR PI0409450A
Authority
BR
Brazil
Prior art keywords
peperacillin
useful
injection
compositions containing
tazobactam
Prior art date
Application number
BRPI0409450-6A
Other languages
English (en)
Inventor
Jonathan Marc Cohen
Syed Muzafar Shah
Christian Luther Ofslager
Mahdi Bakir Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0409450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0409450A publication Critical patent/BRPI0409450A/pt
Publication of BRPI0409450B1 publication Critical patent/BRPI0409450B1/pt
Publication of BRPI0409450B8 publication Critical patent/BRPI0409450B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"COMPOSIçõES QUE CONTêM PEPERACILINA E TAZOBACTAMO, úTEIS PARA INJEçãO". Constatou-se que um agente quelador de ácido aminocarboxílico, preferivelmente, EDTA, ou um sal do mesmo é útil para inibir a formação de partículas em combinações parenterais de piperacilina/tazobactamo. A composição também pode conter um tamponador, preferivelmente, citrato, e, opcionalmente, um aminoglicosídio. O produto pode estar na forma de uma composição congelada, que pode ser descongelada para uso. O produto também pode estar na forma de um pó criodessecado, que pode ser reconstituído por adição de um veículo aquoso, para tornar a formar uma solução.
BRPI0409450A 2003-04-14 2004-04-07 composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos BRPI0409450B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46280803P 2003-04-14 2003-04-14
PCT/US2004/010698 WO2004091666A1 (en) 2003-04-14 2004-04-07 Compositions containing piperacillin and tazobactam useful for injection

Publications (3)

Publication Number Publication Date
BRPI0409450A true BRPI0409450A (pt) 2006-05-02
BRPI0409450B1 BRPI0409450B1 (pt) 2016-07-12
BRPI0409450B8 BRPI0409450B8 (pt) 2021-05-25

Family

ID=32326726

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409450A BRPI0409450B8 (pt) 2003-04-14 2004-04-07 composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos

Country Status (35)

Country Link
US (3) US7498312B2 (pt)
EP (1) EP1468697B1 (pt)
JP (1) JP4644659B2 (pt)
KR (1) KR100824554B1 (pt)
CN (1) CN1802179B (pt)
AR (1) AR043863A1 (pt)
AT (1) ATE381947T1 (pt)
AU (1) AU2004229407B2 (pt)
BR (1) BRPI0409450B8 (pt)
CA (1) CA2464258C (pt)
CH (1) CH695185A9 (pt)
CL (1) CL2004000782A1 (pt)
CO (1) CO5700796A2 (pt)
CR (2) CR8035A (pt)
CY (1) CY1108064T1 (pt)
DE (1) DE602004010862T2 (pt)
DK (1) DK1468697T3 (pt)
EC (1) ECSP056100A (pt)
ES (1) ES2298672T3 (pt)
FR (1) FR2853547B1 (pt)
GB (1) GB2400557B (pt)
HK (1) HK1069775A1 (pt)
IL (1) IL171337A (pt)
MX (1) MXPA05010996A (pt)
MY (1) MY139099A (pt)
NO (1) NO20054789L (pt)
NZ (1) NZ543005A (pt)
PL (1) PL1468697T3 (pt)
PT (1) PT1468697E (pt)
RU (2) RU2322980C2 (pt)
SA (1) SA04250119B1 (pt)
SI (1) SI1468697T1 (pt)
TW (1) TWI308069B (pt)
WO (1) WO2004091666A1 (pt)
ZA (1) ZA200508315B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003299795A1 (en) 2002-12-20 2004-07-22 Xeris Pharmaceuticals, Inc. Intracutaneous injection
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
BRPI0516583A (pt) * 2004-10-14 2008-09-16 Wyeth Corp composição farmacêutica e método de tratamento de uma infecção bacteriana
SI1841432T1 (sl) * 2004-12-02 2011-02-28 Venus Remedies Ltd Sestavki za obrambo proti odpornosti na antibiotike, ki jo povzroäśa beta-laktamaza z uporabo inhibitorja beta-laktamaze primernega za injektiranje
ES2284318B1 (es) * 2005-04-13 2008-11-01 Labiana Development, S.L. Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it) * 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN1927201B (zh) * 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN102210679B (zh) * 2006-08-25 2013-03-13 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN102441169A (zh) * 2006-08-25 2012-05-09 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
EP2642992B1 (en) 2010-11-25 2020-11-25 Allecra Therapeutics GmbH Compounds and their use
WO2012122535A2 (en) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
JP5625081B2 (ja) 2012-03-26 2014-11-12 参天製薬株式会社 ジクアホソル含有点眼液
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) * 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
EA029090B1 (ru) 2013-03-15 2018-02-28 Мерк Шарп И Доум Корп. Антибактериальные фармацевтические композиции, содержащие цефтолозан и тазобактам, и контейнер с дозированной лекарственной формой, содержащей композиции
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274990A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
ES2800603T3 (es) 2013-09-09 2021-01-04 Merck Sharp & Dohme Tratamiento de infecciones con ceftolozano/tazobactam en sujetos con insuficiencia renal
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN106573106B (zh) 2014-08-06 2021-06-22 Xeris药物公司 用于皮内和/或皮下注射糊剂的注射器、试剂盒和方法
TW201626987A (zh) * 2014-10-08 2016-08-01 澤井製藥股份有限公司 凍結乾燥製劑之製造方法
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2017168394A1 (en) * 2016-03-31 2017-10-05 Wockhardt Limited Antibacterial compositions
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US11110054B2 (en) * 2018-05-09 2021-09-07 Slayback Pharma Llc Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4534977A (en) 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4477452A (en) 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US5763480A (en) * 1994-02-14 1998-06-09 The Jewish Hospital Of St. Louis Inhibitors of cell-medicated disorders
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
EP1499341A4 (en) * 2002-04-18 2010-10-27 Univ Iowa Res Found PROCESS FOR INHIBITING AND PROCESSING BIOLOGICAL FILMS USING METAL CHELATORS
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
AU2003230899A1 (en) * 2003-04-14 2004-11-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection

Also Published As

Publication number Publication date
NO20054789L (no) 2005-12-13
CO5700796A2 (es) 2006-11-30
NO20054789D0 (no) 2005-10-18
US7498312B2 (en) 2009-03-03
CH695185A9 (fr) 2006-02-28
US7915229B2 (en) 2011-03-29
ECSP056100A (es) 2006-03-01
AU2004229407B2 (en) 2010-04-22
PL1468697T3 (pl) 2008-05-30
GB2400557A (en) 2004-10-20
JP4644659B2 (ja) 2011-03-02
FR2853547A1 (fr) 2004-10-15
CA2464258C (en) 2005-06-07
CN1802179A (zh) 2006-07-12
CR9792A (es) 2008-09-23
CN1802179B (zh) 2011-09-14
CR8035A (es) 2006-05-30
MY139099A (en) 2009-08-28
TW200503758A (en) 2005-02-01
RU2005135135A (ru) 2006-06-10
US8133883B2 (en) 2012-03-13
GB2400557B (en) 2005-06-15
RU2322980C2 (ru) 2008-04-27
MXPA05010996A (es) 2005-12-12
DE602004010862D1 (de) 2008-02-07
PT1468697E (pt) 2008-03-05
ATE381947T1 (de) 2008-01-15
RU2007142454A (ru) 2009-05-27
US20060234995A1 (en) 2006-10-19
CL2004000782A1 (es) 2005-03-04
ZA200508315B (en) 2008-04-30
HK1069775A1 (en) 2005-06-03
US20110166091A1 (en) 2011-07-07
US20090176720A1 (en) 2009-07-09
EP1468697A1 (en) 2004-10-20
TWI308069B (en) 2009-04-01
ES2298672T3 (es) 2008-05-16
FR2853547B1 (fr) 2006-08-04
DE602004010862T2 (de) 2009-01-02
SA04250119B1 (ar) 2008-03-30
JP2006523695A (ja) 2006-10-19
CH695185A5 (fr) 2006-01-13
SI1468697T1 (sl) 2008-04-30
AR043863A1 (es) 2005-08-17
WO2004091666A1 (en) 2004-10-28
CY1108064T1 (el) 2014-02-12
EP1468697B1 (en) 2007-12-26
BRPI0409450B8 (pt) 2021-05-25
CA2464258A1 (en) 2004-10-14
GB0407853D0 (en) 2004-05-12
KR20060014375A (ko) 2006-02-15
KR100824554B1 (ko) 2008-04-24
BRPI0409450B1 (pt) 2016-07-12
WO2004091666A8 (en) 2005-11-10
AU2004229407A1 (en) 2004-10-28
DK1468697T3 (da) 2008-04-14
NZ543005A (en) 2009-03-31
IL171337A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
BRPI0409450A (pt) composições que contêm peperacilina e tazobactamo, úteis para injeção
BR0108828A (pt) Formulação de carboidrato (adjuvante pré-biótico) para aperfeiçoamento de resposta imuno
BRPI0408382A (pt) composição contendo materiais de zinco particulado que têm um tamanho definido de cristalito
MXPA03000251A (es) Medio de almacenamiento y conservacion para materiales biologicos.
AR046933A1 (es) Eficacia de humectacion mejorada mediante el uso de hidroxialquilurea
PA8774901A1 (es) Productos de cuidado oral y metodos para usar y fabricar el mismo
BRPI0516105A (pt) composições de fator de crescimento derivado de plaqueta e métodos de uso destas
BR0314690A (pt) Goma de mascar revestida
AR065887A1 (es) Producto para el cuidado oral y metodos de uso y fabricacion de los mismos
GT201200192A (es) Composición acuosa antitranspirante / desodorante
CR9887A (es) Composiciones acidas para limpieza
BR9910490A (pt) Materiais e métodos para criar insetos, ácaros e outros organismos benéficos
JP2009509025A5 (pt)
WO2007112272A3 (en) Formulations of low dose diclofenac and beta-cyclodextrin
BRPI0512923A (pt) materiais e métodos para melhorar a saúde, imunidade e crescimento de mariscos
CR20200548A (es) Anticuerpos para radionúclidos quelados
CY1113235T1 (el) Συνθεσεις περιλαμβανουσες αργινινη και r-α-λιποϊκο οξυ και χρηση αυτων για βελτιωση της σεξουαλικης λειτουργιας
BR0013847A (pt) Uso de lubrificantes com compostos de polihidróxi
AR020790A1 (es) Una composicion para extraer sales metalicas divalentes, un metodo para prepararla y su uso para reducir los depositos de sales metalicasdivalentes en un sistema acuoso.
TW200640369A (en) Anti-bacterial composition and anti-bacterial material
AR095971A1 (es) Un método de curtido respetuoso del medio ambiente
HUP9801712A2 (hu) Racemizálás ellen stabilizált, cilansetrontartalmú gyógyászati készítmények, előállításuk és a stabilizáló adalékanyagok alkalmazása
PL1637189T3 (pl) Kompozycje kosmetyczne zawierające sól, cyklodekstrynę i co najmniej jeden anionowy środek powierzchniowo czynny oraz ich zastosowania
BR0115421A (pt) Composições multicomponentes contendo quitosana e métodos para prepapar as mesmas
AR071567A1 (es) Sistemas particulados de inhibidores de nitrificacion

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 47/18, 31/43

Ipc: A61K 47/18 (2011.01), A61K 31/43 (2011.01), A61P 3

Free format text: PARA: INT. CL. A61K 47/18, 31/43; A61P 31/04

Ipc: A61K 47/18 (2011.01), A61K 31/43 (2011.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/07/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved
B25G Requested change of headquarter approved